PLoS ONE · 2013 · 12 citations · 53 references
MedicineGeneticsOncologyCancer GeneticsGene ExpressionMolecular OncologyCancer GenomicsCancer TranscriptomicsGastrointestinal Stromal TumorsMolecular Tumor ProfilingOncogene MutationsOncogenic Signaling PathwaysCancer Mutation AnalysisGain-of-function Receptor MutationsLoss-of-function MutationsOncogenic Pathway AnalysisOncogenic Receptor Tyrosine Kinase MutationsTumor Mutation AnalysisTyrosine Kinase ReceptorsWild-type Gastrointestinal Stromal Tumors
OBJECTIVE: Most gain of function mutations of tyrosine kinase receptors in human tumours are hemizygous. Gastrointestinal stromal tumours (GIST) with homozygous mutations have a worse prognosis. We aimed to identify genes differentially regulated by hemizygous and heterozygous KIT mutations. MATERIALS AND METHODS: Expression of 94 genes and 384 miRNA was analysed with low density arrays in five NIH3T3 cell lines expressing the full-length human KIT cDNA wild-type (WT), hemizygous KIT mutation with del557-558 (D6) or del564-581 (D54) and heterozygous WT/D6 or WT/D54. Expression of 5 of these genes and 384 miRNA was then analysed in GISTs samples. RESULTS: Unsupervised and supervised hierarchical clustering of the mRNA and miRNA profiles showed that heterozygous mutants clustered with KIT WT expressing cells while hemizygous mutants were distinct. Among hemizygous cells, D6 and D54 expressing cells clustered separately. Most deregulated genes have been reported as potentially implicated in cancer and severals, as ANXA8 and FBN1, are highlighted by both, mRNA and miRNA analyses. MiRNA and mRNA analyses in GISTs samples confirmed that their expressions varied according to the mutation of the alleles. Interestingly, RGS16, a membrane protein of the regulator of G protein family, correlate with the subcellular localization of KIT mutants and might be responsible for regulation of the PI3K/AKT signalling pathway. CONCLUSION: Patterns of mRNA and miRNA expression in cells and tumours depend on heterozygous/hemizygous status of KIT mutations, and deletion/presence of TYR568 & TYR570 residues. Thus each mutation of KIT may drive specific oncogenic pathways.
53
Gain-of-Function Mutations of c- <i>kit</i> in Human Gastrointestinal Stromal Tumors
Seiichi Hirota, Koji Isozaki, Y Moriyama et al. · Science · 1998 · 4.5K citations
<i>PDGFRA</i> Activating Mutations in Gastrointestinal Stromal Tumors
Michael C. Heinrich, Christopher L. Corless, Anette Duensing et al. · Science · 2003 · 2.3K citations
Charles D. Blanke, Cathryn Rankin, George D. Demetri et al. · Journal of Clinical Oncology · 2008 · 1.1K citations
Medicine, Oncology, Pharmacotherapy +13